- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Locally advanced (Stage III) or metastatic (Stage IV) urothelial cancer
- Meeting Date: November 2022
- Public Summary Document (PSD) November 2022 PBAC Meeting - (PDF 516KB)
- Public Summary Document (PSD) November 2022 PBAC Meeting - (Word 154KB)
Pembrolizumab – November 2022
Pembrolizumab (urothelial carcinoma): Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda®
Last updated
30 May 2025